Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report

Thumbnail Image

Files

fac_PatelTushar_JournalofHematology&Oncology_2008_1_18.pdf (367.78 KB)

Date

2008-10-17

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

BioMed Central

Research Projects

Organizational Units

Journal Issue

Abstract

Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.

Description

Keywords

Citation

Brian J. So et al, "Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report," Journal of Hematology & Oncology 1 (2008), doi:10.1186/1756-8722-1-18, http://www.jhoonline.org/content/1/1/18

URI

http://hdl.handle.net/1811/47819

Collections

Ohio State University Research and Scholarship